Glucose conjugated aza-BODIPY for enhanced photodynamic cancer therapy

Abstract

Compared with normal cells, cancer cells usually exhibit an increase in glucose uptake as part of the Warburg effect. To take advantage of this hallmark of cancer, glucose transporters could...

Photodynamic Therapy by Glucose Transporter 1-Selective Light Inactivation

“…We speculated that the specific knockdown of GLUT1 might result in cancer cell-specific cytotoxicity. Although several reports have been published on conjugates of glucose and photosensitizers that display tumor-selective accumulation via GLUTs, 25,26 the present study represents the first demonstration of PDT based on GLUT1-selective protein knockdown. In detail, we evaluated the protein inactivation ability of several photosensitizers and found di-iodinated boron dipyrromethene (I 2 BODIPY) to exhibit excellent protein inactivation activity in vitro.…”

A fluorescent chemosensor based on β-N-glycosyl and coumarin for sensing of Hg(II) ions in acetonitrile

“…[7][8][9][10] It is well-known that carbohydrates are very useful in the design of effective chemosensors because of their merits such A fluorescent chemosensor based on β-N-glycosyl and coumarin for sensing of Hg(II) ions in acetonitrile as high hydrophilicity, flexible stereo-structures, low toxicity and biological compatibility, 11,12 and are usually called fluorescent glycoconjugates. Many fluorophores-such as rhodamine, 13,14 fluorescein, 15 dicyanomethylene 4H-pyran, 16 tetraphenylethylene, 17 1,8-naphthalimide, 18 tetraphenylethylene (TPE), 19 and boron-dipyrromethene (BODIPY) 20 have been conjugated with carbohydrates, producing structurally and functionally diverse fluorescent glycoclusters, which can recognize different ions or proteins.…”

Exploring Carbohydrates for Therapeutics: A Review on Future Directions

“…Furthermore, carbohydrates (glucose or other glucose transporter substrates) have been conjugated to cytotoxins or anticancer therapeutics for the specific targeting and treatment of cancer ( Calvaresi and Hergenrother, 2013 ). The rationale behind this strategy is that glucose transporters and glycolytic enzymes are widely overexpressed in cancer tissues, which highly correlates with poor cancer prognosis, thus making them attractive therapeutic targets for achieving anticancer drug targeting ( Treekoon et al, 2021 ). The wide application of 18 F-FDG injection in diagnosis and staging of many types of cancer provides the strongest support to this theory.…”